{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:13:15Z","timestamp":1761862395918},"reference-count":134,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.bpg.2004.09.001","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T01:41:18Z","timestamp":1103161278000},"page":"1049-1072","source":"Crossref","is-referenced-by-count":10,"title":["Modern, new pharmacotherapy for obesity. A gastrointestinal approach"],"prefix":"10.1016","volume":"18","author":[{"given":"L.","family":"Van Gaal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ballaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Verkade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2004.09.001_bib1","first-page":"S76","article-title":"The insulin resistance-dyslipidemic syndrome: contribution to visceral obesity and therapeutic implications","volume":"19","author":"Despr\u00e8s","year":"1995","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib2","series-title":"Clinical Obesity","first-page":"205","article-title":"Effects of obesity on cardiovascular system and blood pressure control, digestive disease and cancer","author":"Van Gaal","year":"1998"},{"key":"10.1016\/j.bpg.2004.09.001_bib3","series-title":"Handbook of Obesity","first-page":"875","article-title":"Dietary treatment of obesity","author":"Van Gaal","year":"1998"},{"issue":"supplement 1","key":"10.1016\/j.bpg.2004.09.001_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.ijo.0800795","article-title":"Pharmacological tretment of obesity: present status","volume":"23","author":"Scheen","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.bpg.2004.09.001_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/er.20.6.805","article-title":"Current and potential drugs for treatment of obesity","volume":"20","author":"Bray","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpg.2004.09.001_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1146\/annurev.ph.45.030183.003251","article-title":"Lipid digestion and absorption","volume":"45","author":"Carey","year":"1983","journal-title":"Ann Rev Physiol"},{"key":"10.1016\/j.bpg.2004.09.001_bib7","first-page":"189","article-title":"Digestion and absorption of fat","volume":"3","author":"Carey","year":"1992","journal-title":"Semin Gastroint Dis"},{"key":"10.1016\/j.bpg.2004.09.001_bib8","series-title":"Intestinal Lipid Metabolism","first-page":"1","article-title":"Biophysics of intestinal luminal lipids","author":"Verkade","year":"2001"},{"key":"10.1016\/j.bpg.2004.09.001_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/0016-5085(88)90354-X","article-title":"Human preduodenal lipase is entirely of gastric fundic origin","volume":"95","author":"Moreau","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.09.001_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0005-2760(89)90012-X","article-title":"Gastric lipases: biochemical and physiological studies","volume":"1006","author":"Gargouri","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bpg.2004.09.001_bib11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0016-5085(86)90695-5","article-title":"Kinetic assay of human gastric lipase on short- and long-chain triacylglycerol emulsions","volume":"91","author":"Gargouri","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.09.001_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0005-2760(86)90234-1","article-title":"Importance of human gastric lipase for intestinal lipolysis: an in vitro study","volume":"879","author":"Gargouri","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bpg.2004.09.001_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ajcn\/62.1.74","article-title":"Dietary fat modulates gastric lipase activity in healthy humans","volume":"62","author":"Armand","year":"1995","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI110599","article-title":"Hydrolysis of milk fat globules by pancreatic lipase. Role of colipase, phospholipase A2, and bile salts","volume":"70","author":"Borgstrom","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpg.2004.09.001_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.432636","article-title":"Watching fat digestion","volume":"204","author":"Patton","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.bpg.2004.09.001_bib16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0022-2275(20)38789-7","article-title":"Enterohepatic circulation in man. A simple method for the determination of duodenal bile acids","volume":"27","author":"Vonk","year":"1986","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib17","doi-asserted-by":"crossref","first-page":"138S","DOI":"10.1002\/hep.1840040824","article-title":"Bile salt structure and phase equilibria in aqueous bile salt and bile salt-lecithin systems","volume":"4","author":"Carey","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2004.09.001_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-2275(20)38331-0","article-title":"Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions","volume":"30","author":"Heuman","year":"1989","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1172\/JCI104909","article-title":"The intraluminal phase of fat lipid digestion in man: the lipid content of the micellar and the oil phases of intestinal contents obtained during fat digestion and absorption","volume":"43","author":"Hofmann","year":"1964","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpg.2004.09.001_bib20","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1021\/bi00460a011","article-title":"Physical\u2013chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings","volume":"29","author":"Staggers","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.bpg.2004.09.001_bib21","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/bi00460a012","article-title":"Physical\u2013chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings","volume":"29","author":"Hernell","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.bpg.2004.09.001_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbalip.2003.08.007","article-title":"Administration of phosphatidylcholine-cholesterol liposomes partially reconstitutes fat absorption in chronically bile-diverted rats","volume":"1636","author":"Nishioka","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bpg.2004.09.001_bib23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.174.4013.1031","article-title":"Unstirred water layer in intestine: rate determinant of fatty acid absorption from micellar solutions","volume":"174","author":"Wilson","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.bpg.2004.09.001_bib24","first-page":"G608","article-title":"Mechanisms maintaining a low-pH microclimate in the intestine","volume":"248","author":"Shiau","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bpg.2004.09.001_bib25","first-page":"G671","article-title":"Acidic mucin layer facilitates micelle dissociation and fatty acid diffusion","volume":"259","author":"Shiau","year":"1990","journal-title":"Am J Physiol"},{"issue":"463\u2013474","key":"10.1016\/j.bpg.2004.09.001_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1113\/jphysiol.1990.sp017955","article-title":"Mechanism of intestinal fatty acid uptake in the rat: the role of an acidic microclimate","volume":"421","author":"Shiau","year":"1990","journal-title":"J Physiol (Lond)"},{"key":"10.1016\/j.bpg.2004.09.001_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0005-2760(96)00041-0","article-title":"Chylomicron assembly and catabolism: role of apolipoproteins and receptors","volume":"1300","author":"Hussain","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bpg.2004.09.001_bib28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0022-2275(20)41980-7","article-title":"Apparent convergence (at 2-monoacylglycerol level) of phosphatidic acid and 2-monoacylglycerol pathways of synthesis of chylomicron triacylglycerols","volume":"32","author":"Yang","year":"1991","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0005-2760(96)00168-3","article-title":"Microsomal triglyceride transfer protein","volume":"1345","author":"Wetterau","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bpg.2004.09.001_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00041433-199404000-00003","article-title":"The molecular basis of abetalipoproteinemia","volume":"5","author":"Gregg","year":"1994","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.bpg.2004.09.001_bib31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0005-2760(78)90025-5","article-title":"The importance of the lysophosphatidylcholine and choline moiety of bile phosphatidylcholine in lymphatic transport of fat","volume":"528","author":"Tso","year":"1978","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bpg.2004.09.001_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0016-5085(00)70426-4","article-title":"Postprandial chylomicron formation and fat absorption in multidrug resistance gene 2 P-glycoprotein-deficient mice","volume":"118","author":"Voshol","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.09.001_bib33","first-page":"79","article-title":"Dietary fat and obesity: evidence from epidemiology","volume":"49","author":"Lissner","year":"1995","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib34","first-page":"S12","article-title":"Mode of action of orlistat","volume":"21","author":"Guerciolini","year":"1997","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/bj2560357","article-title":"Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin","volume":"256","author":"Hadvary","year":"1998","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.bpg.2004.09.001_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1432-1033.1994.tb18878.x","article-title":"Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin","volume":"222","author":"Lockene","year":"1994","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.bpg.2004.09.001_bib37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/009127009603601104","article-title":"Metabolic profiles of minimally absorbed orlistat in obese\/overweight volunteers","volume":"36","author":"Zhi","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bpg.2004.09.001_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/clpt.1994.104","article-title":"Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers","volume":"56","author":"Zhi","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2004.09.001_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0026-0495(94)90095-7","article-title":"Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor","volume":"43","author":"Reitsma","year":"1994","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.bpg.2004.09.001_bib40","doi-asserted-by":"crossref","first-page":"309S","DOI":"10.1093\/ajcn\/55.1.309s","article-title":"Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin)","volume":"55","author":"Hauptman","year":"1992","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"10.1016\/j.bpg.2004.09.001_bib41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/j.1552-4604.1994.tb01990.x","article-title":"Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat","volume":"34","author":"Hussain","year":"1994","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.bpg.2004.09.001_bib42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/j.1552-4604.1995.tb04128.x","article-title":"The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers","volume":"35","author":"Melia","year":"1995","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.bpg.2004.09.001_bib43","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/j.1552-4604.1995.tb04034.x","article-title":"Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers","volume":"35","author":"Zhi","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bpg.2004.09.001_bib44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-199958040-00015","article-title":"Orlistat: a review of its use in the management of obesity","volume":"58","author":"Hvizdos","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.bpg.2004.09.001_bib45","first-page":"241","article-title":"Lipase inhibition: a novel concept in the treatment of obesity","volume":"17","author":"Drent","year":"1993","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib46","first-page":"221","article-title":"Orlistat (Ro18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study","volume":"19","author":"Drent","year":"1995","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002280050433","article-title":"Efficacy and tolerability of orlistat in the treatment of obesity\u2014a 6-month dose-ranging study","volume":"54","author":"Van Gaal","year":"1998","journal-title":"Eur J Clin Pharm"},{"issue":"3","key":"10.1016\/j.bpg.2004.09.001_bib48","first-page":"S24","article-title":"A one-year trial to assess the value of orlistat in the management of obesity","volume":"21","author":"James","year":"1997","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.09.001_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Long-term weight control and risk factor reduction in obese subjects treated with orlistat, a lipase inhibitor","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bpg.2004.09.001_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.ijo.0802165","article-title":"Predictive value of early weight loss in obesity management with orlistat: an evidence based assessment of prescribing guidelines","volume":"27","author":"Rissanen","year":"2003","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib52","first-page":"S5","article-title":"The beneficial effects of modest weight loss on cardiovascular risk factors","volume":"21","author":"Van Gaal","year":"1997","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight recuction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.ijo.0801814","article-title":"The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized double-blind, placebo-controlled, multicenter study","volume":"25","author":"Muls","year":"2001","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlisat Obesity Study Group","volume":"8","author":"R\u00f6ssner","year":"2000","journal-title":"Obes Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year-treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"Int J Obes"},{"issue":"3","key":"10.1016\/j.bpg.2004.09.001_bib57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0005-2760(89)90107-0","article-title":"Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat","volume":"1001","author":"Fernandez","year":"1989","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/j.bpg.2004.09.001_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9149(01)02208-1","article-title":"Usefulness of orlistat in the treatment of severe hypertriglyceridemia","volume":"89","author":"Wierzbicki","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.bpg.2004.09.001_bib59","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2337\/diacare.21.3.350","article-title":"Lifestyle intervention in overweight individuals with a family history of diabetes","volume":"21","author":"Wing","year":"1998","journal-title":"Diab Care"},{"key":"10.1016\/j.bpg.2004.09.001_bib60","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib62","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"Xenical in the prevention of diabetes in obese subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diab Care"},{"key":"10.1016\/j.bpg.2004.09.001_bib64","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diab Care"},{"key":"10.1016\/j.bpg.2004.09.001_bib65","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes mellitus: a one-year, randomized, controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diab Care"},{"key":"10.1016\/j.bpg.2004.09.001_bib66","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effects of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diab Care"},{"key":"10.1016\/j.bpg.2004.09.001_bib67","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"Effect of intensive blood-glucose control with netformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UKPDS Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.09.001_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2337\/diacare.27.1.33","article-title":"Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes","volume":"27","author":"Kelley","year":"2004","journal-title":"Diab Care"},{"key":"10.1016\/j.bpg.2004.09.001_bib69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00044011-199917030-00006","article-title":"Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia","volume":"17","author":"Oo","year":"1999","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.bpg.2004.09.001_bib70","series-title":"Regulators of Intestinal Absorption in Obesity, Diabetes and Nutrition","first-page":"181","article-title":"The clinical significance of the alpha-amylase inhibitors","volume":"vol. 1","author":"Berchtold","year":"1981"},{"key":"10.1016\/j.bpg.2004.09.001_bib71","first-page":"301","article-title":"A study of \u2018starch blockers\u2019 in man using 13C-enriched starch as a tracer","volume":"37","author":"Garrow","year":"1983","journal-title":"Hum Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01851236","article-title":"The effects of the alpha-glucosidase inhibitor Bay g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man","volume":"175","author":"Hildebrand","year":"1979","journal-title":"Res Exp Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01851237","article-title":"The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man","volume":"175","author":"Hildebrand","year":"1979","journal-title":"Res Exp Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib74","first-page":"231","article-title":"Pharmacological significance of glucosidase inhibitors (acarbose)","volume":"vol. 1","author":"Puls","year":"1981"},{"key":"10.1016\/j.bpg.2004.09.001_bib75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0168-8227(95)01065-L","article-title":"An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans","volume":"28","author":"Goto","year":"1995","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.bpg.2004.09.001_bib76","first-page":"147","article-title":"Metabolic improvements associated with a reduction of abdominal visceral fat caused by a new alpha-glucosidase inhibitor, AO-128, in Zucker fatty rats","volume":"13","author":"Kobatake","year":"1989","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib77","first-page":"1","article-title":"Alpha-glucosidase inhibition in obesity","volume":"706","author":"William-Olsson","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.bpg.2004.09.001_bib78","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.ijo.0800468","article-title":"Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes","volume":"21","author":"Wolever","year":"1997","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1463-1326.2001.00141.x","article-title":"Miglitol combined with metformin improves glycaemic control in type 2 diabetes","volume":"3","author":"Van Gaal","year":"2001","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib80","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.09.001_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ajcn\/56.1.84","article-title":"Effects of olestra, a noncaloric fat substitute, on daily energy and fat intakes in lean men","volume":"56","author":"Rolls","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib82","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1079\/BJN19960158","article-title":"Fat substitution and food intake: effect of replacing fat with sucrose polyester at lunch or evening meals","volume":"75","author":"Cotton","year":"1996","journal-title":"Br J Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib83","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/ajcn\/63.6.891","article-title":"Replacement of dietary fat with sucrose polyester: effects on energy intake and appetite control in nonobese males","volume":"63","author":"Cotton","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib84","first-page":"A439","article-title":"Effects of two weeks fat replacement by olestra on food intake and energy metabolism","volume":"J9","author":"Bray","year":"1995","journal-title":"FASEB"},{"key":"10.1016\/j.bpg.2004.09.001_bib85","first-page":"358A","article-title":"Metabolic effects of fat substitution with olestra","volume":"J11","author":"Roy","year":"1997","journal-title":"FASEB"},{"key":"10.1016\/j.bpg.2004.09.001_bib86","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/ajcn\/76.5.928","article-title":"A nine-month randomized clinical trial comparing a fat-substituted and fat-reduced diet in healthy obese men: the Ole Study","volume":"76","author":"Bray","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib87","first-page":"303","article-title":"Growth hormone, insulin-like growth factors, and acromegaly","author":"Daughaday","year":"1995"},{"key":"10.1016\/j.bpg.2004.09.001_bib88","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.80.11.3209","article-title":"Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay","volume":"80","author":"Veldhuis","year":"1995","journal-title":"J Clin Endocrinol"},{"issue":"1\u20133","key":"10.1016\/j.bpg.2004.09.001_bib89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000183761","article-title":"Effects of growth hormone on body fat in adults","volume":"40","author":"Gertner","year":"1993","journal-title":"Hormone Res"},{"issue":"2","key":"10.1016\/j.bpg.2004.09.001_bib90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000182592","article-title":"Growth hormone actions on fat distribution and metabolism","volume":"38","author":"Gertner","year":"1992","journal-title":"Hormone Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib91","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/jcem-33-2-293","article-title":"Effects of triiodothyronine, growth hormone and anabolic steroids on nitrogen excretion and oxygen consumption of obese patients","volume":"33","author":"Bray","year":"1971","journal-title":"J Clin Endo Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib92","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/jc.76.2.309","article-title":"Treatment of adults with growth hormone (GH) deficiency with recombinant human GH","volume":"76","author":"Bengtsson","year":"1993","journal-title":"J Clin Endocrinol"},{"key":"10.1016\/j.bpg.2004.09.001_bib93","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2362.1993.tb00762.x","article-title":"Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy","volume":"23","author":"Brummer","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bpg.2004.09.001_bib94","first-page":"E211","article-title":"Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity","volume":"266","author":"Richelsen","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bpg.2004.09.001_bib95","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0002-9343(99)80396-9","article-title":"Persistent lipolytic effect of exogenous growth hormone during caloric restrictions","volume":"98","author":"Snyder","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib96","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/eje.0.1320565","article-title":"Growth hormone administration in addition to a very low calorie diet and an exercise program in obese subjects","volume":"132","author":"Drent","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bpg.2004.09.001_bib97","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jc.82.3.727","article-title":"Growth hormone treatment of abdominally obese men reduces abdominal fat masse, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure","volume":"82","author":"Johannsson","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib98","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1210\/jc.83.5.1477","article-title":"Effects of human growth hormone, insulin like growth factor and diet and exercise on bhody composition of obese postmenopausal women","volume":"83","author":"Thompson","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib99","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1530\/eje.0.1380408","article-title":"Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men","volume":"138","author":"Karlsson","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bpg.2004.09.001_bib100","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/0016-5085(94)90831-1","article-title":"Glucagonlike peptide 1: a newly discovered gastrointestinal hormone","volume":"107","author":"Holst","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.09.001_bib101","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00060793-199804000-00006","article-title":"Treatment of type 2 diabetes with glucagonlike peptide 1","volume":"5","author":"Holst","year":"1998","journal-title":"Curr Opinion Endocrinol Diab"},{"key":"10.1016\/j.bpg.2004.09.001_bib102","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/jc.86.9.4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2004.09.001_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200060010-00001","article-title":"Promising new approaches to the management of obesity","volume":"60","author":"Mertens","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.bpg.2004.09.001_bib105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1210\/jc.80.3.952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib106","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1073\/pnas.0631828100","article-title":"Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance","volume":"100","author":"Conarello","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.bpg.2004.09.001_bib107","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0014-2999(02)01434-6","article-title":"Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives","volume":"440","author":"Meier","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpg.2004.09.001_bib108","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1079\/BJN20031064","article-title":"Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects","volume":"91","author":"Naslund","year":"2004","journal-title":"Br J Nutr"},{"key":"10.1016\/j.bpg.2004.09.001_bib109","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.physbeh.2004.04.019","article-title":"Glucagon-like peptide 1 (GLP-1) and eating","volume":"82","author":"Gutzwiller","year":"2004","journal-title":"Physiol Behav"},{"key":"10.1016\/j.bpg.2004.09.001_bib111","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02532137","article-title":"Effect of (\u2212)-hydroxycitrate upon the accummulation of lipid in the rat. II. Appetite","volume":"9","author":"Sullivan","year":"1974","journal-title":"Lipids"},{"key":"10.1016\/j.bpg.2004.09.001_bib112","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/0024-3205(93)90491-K","article-title":"The indirect pathway of hepatic glycogen synthesis and reduction of food intake by metabolic inhibitors","volume":"53","author":"Hellerstein","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.bpg.2004.09.001_bib113","first-page":"75","article-title":"Hydroxycitrate in the treatment of obesity","volume":"20","author":"Thom","year":"1996","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib114","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3181\/00379727-218-44285","article-title":"The actions of exogenous dehydroepiandrosterone in experimental animals and humans","volume":"218","author":"Svec","year":"1998","journal-title":"Proc Soc Exp Biol Med"},{"issue":"supplement 4","key":"10.1016\/j.bpg.2004.09.001_bib115","doi-asserted-by":"crossref","first-page":"613S","DOI":"10.1002\/j.1550-8528.1995.tb00234.x","article-title":"Dehydroepiandrosterone and body fat","volume":"3","author":"Clore","year":"1995","journal-title":"Obes Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib116","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0039-128X(97)00159-1","article-title":"Biologically active metabolites and synthetic derivates of dehydroepiandrosterone","volume":"63","author":"Lardy","year":"1998","journal-title":"Steroids"},{"key":"10.1016\/j.bpg.2004.09.001_bib117","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1210\/jcem-71-5-1259","article-title":"Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans","volume":"71","author":"Welle","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib118","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1210\/jcem-57-2-304","article-title":"Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women","volume":"57","author":"Evans","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib119","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1210\/jc.82.5.1528","article-title":"androstane-3\u03b1-17\u03b2-diol glucuronide as a steroid correlate of visceral obesity in men","volume":"82","author":"Tchernof","year":"1997","journal-title":"J Clin End Metabol"},{"issue":"12","key":"10.1016\/j.bpg.2004.09.001_bib120","first-page":"991","article-title":"The effects of testosterone treatment on body composition and metabolism in middle-aged obese men","volume":"16","author":"Marin","year":"1992","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib121","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/j.1550-8528.1993.tb00618.x","article-title":"Androgen treatment of abdominally obese men","volume":"1","author":"Marin","year":"1993","journal-title":"Obes Res"},{"issue":"4","key":"10.1016\/j.bpg.2004.09.001_bib122","doi-asserted-by":"crossref","first-page":"609S","DOI":"10.1002\/j.1550-8528.1995.tb00233.x","article-title":"Testosterone and regional fat distribution","volume":"3","author":"Marin","year":"1995","journal-title":"Obes Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib123","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1210\/jc.81.6.2198","article-title":"Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women\u2014a clinical Research Center Study","volume":"81","author":"Lovejoy","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2004.09.001_bib124","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.ijo.0801935","article-title":"The importance of obesity in diabetes and its treatment with sibutramine. Review","volume":"25","author":"Van Gaal","year":"2001","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"10.1016\/j.bpg.2004.09.001_bib126","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","article-title":"The efficacy and safety of sibutramine for weight loss: a systematic review","volume":"164","author":"Arterburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib127","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.bpg.2004.09.001_bib128","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ajcn\/68.6.1180","article-title":"Thermogenic effects of sibutramine in humans","volume":"68","author":"Hansen","year":"1998","journal-title":"Am J Clin Nutr"},{"issue":"supplement 1","key":"10.1016\/j.bpg.2004.09.001_bib129","first-page":"S38","article-title":"Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal\/visceral fat reduction?","volume":"22","author":"Van Gaal","year":"1998","journal-title":"Int J Obes"},{"key":"10.1016\/j.bpg.2004.09.001_bib130","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.09.001_bib131","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diab Care"},{"issue":"2","key":"10.1016\/j.bpg.2004.09.001_bib132","doi-asserted-by":"crossref","first-page":"R343","DOI":"10.1152\/ajpregu.00706.2002","article-title":"Endogenous cannabinoids: a new target in the treatment of obesity","volume":"284","author":"Kirkham","year":"2003","journal-title":"Am J Physiol (Regul Integr Comp Physiol)"},{"key":"10.1016\/j.bpg.2004.09.001_bib133","unstructured":"Press Release Sanofi Synthelabo, 9 march 2004. Two pivotal studies indicate Rimonabant offers a novel approach to cardiovascular risk management in overweight\/obese people and smokers. Available at http:\/\/www.sanofi-synthelabo.com\/rd\/p_research.asp Accessed 29 July 2004."},{"key":"10.1016\/j.bpg.2004.09.001_bib134","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691804001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691804001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T14:37:14Z","timestamp":1625150234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691804001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":134,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S1521691804001404"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2004.09.001","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}